Clinical trials: Primary Open-angle Glaucoma
- Condition Primary Open-angle Glaucoma
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Primary Open Angle Glaucoma
Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort
The purpose of this study is to assess the long-term safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100R/L in subjects previously enrolled in Glaukos Study GC-003.
- Trial name
- NCT01836042
- Where
- 26 sites in United States
- Volunteers
- 108 people
- Sponsor
- Glaukos Corporation
Glaucoma, Open-Angle
An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in…
- Trial name
- NCT04872348
- Testing
- OMNI® Surgical System
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sight Sciences, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study and will evaluate IOP reduction in newly diagnosed patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians…
- Trial name
- NCT01628614
- Testing
- Standard of Care
- Where
- Spain
- Volunteers
- 4,812 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01632423
- Testing
- bimatoprost 0.01%
- Where
- Germany
- Volunteers
- 10,337 people
- Sponsor
- Allergan
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma, Ocular Hypertension
Study of TRAVATAN in Subjects With Iris Pigmentation Changes
The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00047554
- Testing
- Travoprost, 0.004% ophthalmic solution
- Volunteers
- 336 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
This is an observational study of patients diagnosed with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) who are insufficiently responsive to monotherapy and who are prescribed GANfort® (fixed combination of 0.3…
- Trial name
- NCT01628601
- Testing
- Fixed combination 0.3 mg bimatoprost and 5 mg timolol
- Where
- Austria
- Volunteers
- 392 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Glaucoma Primary Open Angle
Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
The objective of this phase IV clinical multi-center trial will be to compare the efficacy and safety of Ganforti® versus Krytantek®, using a cross-over design during a six month period (including a one-month wash-in period) in…
- Trial name
- NCT01737853
- Testing
- Ganforti, Krytantek
- Where
- 4 sites in Mexico
- Volunteers
- 90 people
- Sponsor
- Allergan S.A. DE C.V..
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
The study will evaluate patients diagnosed with POAG or OHT who are switched to GANFORT® UD (unit dose of fixed combination bimatoprost and timolol) therapy for medical reasons in accordance with physician standard clinical…
- Trial name
- NCT01999348
- Testing
- Fixed Combination Bimatoprost and Timolol
- Where
- Germany
- Volunteers
- 1,553 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy
This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.
- Trial name
- NCT01637246
- Testing
- Any Fixed Combination Therapy
- Where
- Spain
- Volunteers
- 4,385 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to…
- Trial name
- NCT01589510
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Austria
- Volunteers
- 419 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.15% brimonidine tartrate in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- APOTUS (NCT02003534)
- Testing
- 0.15% Brimonidine Tartrate
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01628588
- Testing
- bimatoprost 0.01%
- Where
- Netherlands
- Volunteers
- 854 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
- Trial name
- NCT01646151
- Testing
- Bimatoprost
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 2,580 people
- Sponsor
- Allergan
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
The study will evaluate patients diagnosed with primary open angle glaucoma or ocular hypertension who are switched to Lumigan® UD monotherapy for medical reasons in accordance with physician standard clinical practice.
- Trial name
- NCT01853085
- Testing
- Bimatoprost Ophthalmic Solution
- Where
- Germany
- Volunteers
- 1,830 people
- Sponsor
- Allergan